VRTXNASDAQ— Vertex Pharmaceuticals Inc Price & Analysis

Vertex Pharmaceuticals Inc

HEALTHCARE — BIOTECHNOLOGY

$546.12

-$11.84-2.12%

Market Cap: $141.42B; Large Cap
P/E Ratio: 32.46; Fwd: 25.58
EPS (TTM): $17.19
Div. Yield: N/A

Technical Summary

RSI (14)59.36Neutral

SMA (50)$508.76Bullish

SMA (200)$466.15Bullish

MACD14.7567Bearish

Bollinger$509.55 – $568.00Mid

Stochastic86.74Overbought

Theo Outlook

Vertex Pharmaceuticals (VRTX) presents a bullish thesis with a market capitalization of $138.42 billion, a trailing P/E of 31.84, and EPS of $17.15. Revenue TTM stands at $12.59 billion with 12.5% quarterly revenue growth year-over-year, supported by a 35% profit margin and 23.5% return on equity. The forward P/E of 26.04 suggests reasonable valuation relative to growth in the biotechnology sector. Key catalysts include strong earnings momentum from cystic fibrosis therapies and pipeline expansion into new indications, with analyst ratings showing 4 strong buy and 19 buy recommendations alongside a target price of $569.54. Recent quarterly earnings growth of 8% and revenue growth of 12.5% highlight operational leverage, while the low beta of 0.32 indicates defensive characteristics amid sector volatility. Risks encompass regulatory hurdles for new drug approvals, intense competition in rare disease treatments, and macroeconomic pressures on healthcare spending. Mitigations include Vertex's robust cash position, diversified pipeline, and high institutional ownership at 98.1%, which provides stability and access to capital for R&D advancement. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Analysis generated by HeyTheo AI on Sep 7, 2026.

Company Overview

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Fundamental Snapshot

Revenue: $12.59B
EBITDA: $5.10B
Gross Profit: $6.92B
Operating Margin: 38.1%
Profit Margin: 35.0%
ROE: 23.5%
Book Value: $79.92
Beta: 0.31
52-Wk High: $560.25
52-Wk Low: $374.17
Avg Volume: 800.09K
PEG Ratio: 1.67

Frequently Asked Questions

What is Vertex Pharmaceuticals' business model?

Vertex Pharmaceuticals develops and commercializes therapies for serious diseases, primarily cystic fibrosis, with a focus on small-molecule drugs. The company reported TTM revenue of $12.59 billion and EPS of $17.15, generating a 35% profit margin. It operates without a dividend, reinvesting heavily in R&D.

What are Vertex's main revenue sources?

Revenue primarily comes from cystic fibrosis treatments, contributing to $12.59 billion TTM revenue with 12.5% quarterly growth. The company has expanded into additional rare disease areas, supported by a 31.84 trailing P/E and strong institutional ownership of 98.1%.

What competitive advantages does Vertex hold?

Vertex benefits from a dominant position in cystic fibrosis with high barriers to entry, a 23.5% return on equity, and a low beta of 0.32 for stability. Its pipeline and analyst target price of $569.54 reflect strong competitive moats in biotechnology.

What are the key risks for VRTX investors?

Key risks include regulatory approval delays, competition in biotech, and macro healthcare spending pressures. With a forward P/E of 26.04 and no dividend yield, investors should monitor earnings dates and quarterly revenue growth of 12.5% for mitigation through pipeline diversification.

What is the growth outlook for Vertex Pharmaceuticals?

Growth outlook remains positive with 8% quarterly earnings growth, 12.5% revenue growth, and analyst ratings favoring buys. The $138.42 billion market cap and 50-day moving average of $508.76 support expansion, though investors should watch the 52-week range of $374.17-$560.25.